Clinical Trial Update: A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravitreal lampalizumab every two or four weeks in geographic atrophy completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• lampalizumab (lampalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Geographic Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2019-02-19